Video

Dr. Pennell on Understanding the Cost-Effectiveness of Osimertinib in NSCLC

Nathan A. Pennell, MD, PhD, discusses the importance of understanding the cost-effectiveness of osimertinib in non–small cell lung cancer.

Nathan A. Pennell, MD, PhD, an associate professor in the Department of Medicine and director of the Lung Cancer Medical Oncology Program at the Taussig Cancer Institute of Cleveland Clinic, discusses the importance of understanding the cost-effectiveness of osimertinib (Tagrisso) in non–small cell lung cancer (NSCLC).

During the 2021 ASCO Annual Meeting, findings from a cost-effectiveness analysis of adjuvant osimertinib in patients with resected, EGFR-mutant NSCLC were presented. The results demonstrated that adjuvant osimertinib is cost-effective if one is willing to pay $317,119 more per quality-adjusted life years–gained.

Currently, osimertinib is approved by the FDA for use in this patient population and is often covered by insurance, says Pennell. However, in countries other than the United States, cost-effectiveness may be considered more often as a determinant in treatment selection, Pennell explains.

As such, treatment with osimertinib should not be considered cost-ineffective, but it is important for providers and patients to understand the cost of treatments, such as osimertinib, in all situations, concludes Pennell.

Related Videos
Victor Moreno, MD, PhD
Tiago Biachi, MD, PhD
Dr Girard on De Novo and Acquired Resistance Alterations in HER2-Altered NSCLC
Haley M. Hill, PA-C, discusses the role of multidisciplinary management in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the next steps for biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on tissue and liquid biopsies for biomarker testing in NSCLC.